The MATE trial: a multicentre, mixed‑methodology, pilot, randomised controlled trial in neovascular age‑related macular degeneration
The MATE trial: a multicentre, mixed‑methodology, pilot, randomised controlled trial in neovascular age‑related macular degeneration
Biosimilar SB11 versus reference ranibizumab in neovascular age‑related macular degeneration: 1‑year phase III randomised clinical trial outcomes
Biosimilar SB11 versus reference ranibizumab in neovascular age‑related macular degeneration: 1‑year phase III randomised clinical trial outcomes
Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration
Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration
Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial
Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results